Pluri Inc
NASDAQ:PLUR

Watchlist Manager
Pluri Inc Logo
Pluri Inc
NASDAQ:PLUR
Watchlist
Price: 4.58 USD -4.98%
Market Cap: 25.5m USD
Have any thoughts about
Pluri Inc?
Write Note

Pluri Inc
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Pluri Inc
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
Pluri Inc
NASDAQ:PLUR
Other Long-Term Assets
$1.2m
CAGR 3-Years
19%
CAGR 5-Years
11%
CAGR 10-Years
5%
Collplant Biotechnologies Ltd
NASDAQ:CLGN
Other Long-Term Assets
$57k
CAGR 3-Years
-32%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Kamada Ltd
NASDAQ:KMDA
Other Long-Term Assets
$143.2m
CAGR 3-Years
157%
CAGR 5-Years
146%
CAGR 10-Years
107%
Urogen Pharma Ltd
NASDAQ:URGN
Other Long-Term Assets
$545k
CAGR 3-Years
-35%
CAGR 5-Years
40%
CAGR 10-Years
N/A
Entera Bio Ltd
NASDAQ:ENTX
Other Long-Term Assets
$20k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bonus Biogroup Ltd
TASE:BONS
Other Long-Term Assets
â‚Ş374k
CAGR 3-Years
-7%
CAGR 5-Years
31%
CAGR 10-Years
N/A
No Stocks Found

Pluri Inc
Glance View

Market Cap
25.2m USD
Industry
Biotechnology

Pluri Inc is a IL-based company operating in Biotechnology industry. Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The firm's products include PLX-PAD and PLX R18. The firm's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The firm's PLX products are administered using a standard needle and syringe. The firm's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.

PLUR Intrinsic Value
1.42 USD
Overvaluation 69%
Intrinsic Value
Price

See Also

What is Pluri Inc's Other Long-Term Assets?
Other Long-Term Assets
1.2m USD

Based on the financial report for Sep 30, 2024, Pluri Inc's Other Long-Term Assets amounts to 1.2m USD.

What is Pluri Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
5%

Over the last year, the Other Long-Term Assets growth was 12%. The average annual Other Long-Term Assets growth rates for Pluri Inc have been 19% over the past three years , 11% over the past five years , and 5% over the past ten years .

Back to Top